TITLE

Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature

PUB. DATE
January 2008
SOURCE
BMC Genetics;2008, Vol. 9, p339
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
43750124

 

Related Articles

  • A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. Paik, Soonmyung; Shak, Steven; Tang, Gong; Kim, Chungyeul; Baker, Joffre; Cronin, Maureen; Baehner, Frederick L.; Walker, Michael G.; Watson, Drew; Park, Taesung; Hiller, William; Fisher, Edwin R.; Wickerham, D. Lawrence; Bryant, John; Wolmark, Norman // New England Journal of Medicine;12/30/2004, Vol. 351 Issue 27, p2817 

    Background: The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor–positive tumors is poorly defined by clinical and histopathological measures. Methods: We tested whether the results of a...

  • Comparison of prognostic gene expression signatures for breast cancer. Haibe-Kains, Benjamin; Desmedt, Christine; Piette, Fanny; Buyse, Marc; Cardoso, Fatima; van't Veer, Laura; Piccart, Martine; Bontempi, Gianluca; Sotiriou, Christos // BMC Genomics;2008, Vol. 9, Special section p1 

    Background: During the last years, several groups have identified prognostic gene expression signatures with apparently similar performances. However, signatures were never compared on an independent population of untreated breast cancer patients, where risk assessment was computed using the...

  • Prognostic Value of Gene Signatures and Proliferation in Lymph-Node-Negative Breast Cancer. Jonsdottir, Kristin; Assmus, Jörg; Slewa, Aida; Gudlaugsson, Einar; Skaland, Ivar; Baak, Jan P. A.; Janssen, Emiel A. M. // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Introduction: The overall survival rate is good for lymph-node-negative breast cancer patients, but they still suffer from serious over- and some undertreatments. Prognostic and predictive gene signatures for node-negative breast cancer have a high number of genes related to proliferation. The...

  • Multiple Gene Signatures Aim to Qualify Risk in Breast Cancer. Tuma, Rabiya S. // JNCI: Journal of the National Cancer Institute;3/2/2005, Vol. 97 Issue 5, p332 

    Identifies a gene signature that detects women at high and low risk of breast cancer recurrence in the Netherlands. Treatment of women with node-negative breast cancer; Correlation of activated pattern with metastasis and overall survival; Risk factors for the disease.

  • Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. Buyse, Marc; Loi, Sherene; van't Veer, Laura; Viale, Giuseppe; Delorenzi, Mauro; Glas, Annuska M.; Saghatchian d'Assignies, Mahasti; Bergh, Jonas; Lidereau, Rosette; Ellis, Paul; Harris, Adrian; Bogaerts, Jan; Therasse, Patrick; Floore, Arno; Amakrane, Mohamed; Piette, Fanny; Rutgers, Emiel; Sotiriou, Christos; Cardoso, Fatima; Piccart, Martine J. // JNCI: Journal of the National Cancer Institute;9/6/2006, Vol. 98 Issue 17, p1183 

    Background: A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal was to validate the signature in an independent group of patients. Methods: Patients (n = 307, with 137 events after a median follow-up of 13.6 years) from five...

  • Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms. Drukker, C.; Nijenhuis, M.; Bueno-de-Mesquita, J.; Retèl, V.; Harten, W.; Tinteren, H.; Wesseling, J.; Schmidt, M.; Veer, L.; Sonke, G.; Rutgers, E.; Vijver, M.; Linn, S. // Breast Cancer Research & Treatment;Jun2014, Vol. 145 Issue 3, p697 

    Clinical guidelines for breast cancer treatment differ in their selection of patients at a high risk of recurrence who are eligible to receive adjuvant systemic treatment (AST). The 70-gene signature is a molecular tool to better guide AST decisions. The aim of this study was to evaluate whether...

  • Gene-expression assays: New tools to individualize treatment of early-stage breast cancer. Dobbe, Elizabeth; Gurney, Kristen; Kiekow, Sara; Lafferty, Jeffery S.; Kolesar, Jill M. // American Journal of Health-System Pharmacy;1/1/2008, Vol. 65 Issue 1, p23 

    Purpose. The clinical and economic data for the two currently available gene-expression assays are reviewed. Summary. Two gene-expression assays, used to determine the risk of breast cancer recurrence in patients with stage I or II node-negative breast cancer, are currently available. Oncotype...

  • Infrequent Loss of Luminal Differentiation in Ductal Breast Cancer Metastasis. Calvo, Julia; Sánchez-Cid, Lourdes; Muñoz, Montserrat; Lozano, Juan José; Thomson, Timothy M.; Fernández, Pedro L. // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Lymph node involvement is a major prognostic variable in breast cancer. Whether the molecular mechanisms that drive breast cancer cells to colonize lymph nodes are shared with their capacity to form distant metastases is yet to be established. In a transcriptomic survey aimed at identifying...

  • Genetic Signature Could Identify Breast Cancer Patients at Risk of Recurrence. Zielinski, Sarah L. // JNCI: Journal of the National Cancer Institute;3/16/2005, Vol. 97 Issue 6, p415 

    Reports on the results of a study concerning the ability of 76-gene signature to predict which breast cancer patients are most likely to experience a distant recurrence. Findings that 76-gene signature would indicate chemotherapy for only 52 percent of low-risk patients; Conclusion that gene...

  • Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Prat, A.; Parker, J. S.; Fan, C.; Cheang, M. C. U.; Miller, L. D.; Bergh, J.; Chia, S. K. L.; Bernard, P. S.; Nielsen, T. O.; Ellis, M. J.; Carey, L. A.; Perou, C. M. // Annals of Oncology;Nov2012, Vol. 23 Issue 11, p2866 

    Background ER-positive (ER+ ) breast cancer includes all of the intrinsic molecular subtypes, although the luminal A and B subtypes predominate. In this study, we evaluated the ability of six clinically relevant genomic signatures to predict relapse in patients with ER+ tumors treated with...

Share

Other Topics